Pearl matrixBone Graft The PearlMatrix P-15 Peptide Enhanced Bone Graft has achieved a significant milestone with its FDA approval, marking a new era in spinal fusion procedures. This innovative bone graft solution, developed by Cerapedics, is recognized as the first and only bone growth accelerator specifically designed to expedite lumbar fusion. The approval signifies a critical step forward, offering enhanced therapeutic options for patients undergoing spinal fusion surgeries.Premarket Approval (PMA) - FDA
PearlMatrix P-15 Peptide Enhanced Bone Graft is a sophisticated biomaterial designed to promote and accelerate the natural bone healing process. At its core is the proprietary P-15 peptide, a synthetic 15-amino acid polypeptide sequence that mimics the cell-binding domain of collagen. This peptide is adsorbed onto an anorganic bone mineral (ABM) matrix, creating a composite graft that facilitates cellular adhesion, proliferation, and differentiation, ultimately leading to faster and more robust bone formation.
The P-15 peptide's ability to bind to bone cells acts as a crucial signaling mechanism, encouraging osteoblasts to attach and begin the process of osteogenesis.2025年6月24日—"The FDA approval ofPearlMatrix Bone Graftis a significant achievement for Cerapedics as we're the only company with two PMA-approved products ... This targeted approach distinguishes PearlMatrix from traditional bone grafts, which rely solely on the inherent biological properties of the graft material. The P-15 peptide enhances the bioactivity of the graft, making it a powerful tool for surgeons aiming to achieve solid fusions efficiently.
The journey to FDA approval for PearlMatrix P-15 Peptide Enhanced Bone Graft has been marked by several key regulatory achievements. Cerapedics initially received FDA Breakthrough Device designation for PearlMatrix in 2021, a testament to its potential to address unmet clinical needs in spinal fusion.Cerapedics Receives FDA Approval for PearlMatrix Bone ... This designation paved the way for a streamlined review process.FDA Approves First Bone Growth Accelerator for Spinal ...
The pivotal moment arrived with the Premarket Approval (PMA) from the FDA, with multiple sources indicating June 18, 2025, as the official date of notice. This comprehensive review process confirmed the safety and effectiveness of PearlMatrix for its intended use, specifically in accelerating lumbar fusion. Subsequent announcements confirmed the PearlMatrix Bone Graft received U.S. FDA premarket approval in June 2025, underscoring the significance of this regulatory clearance. The FDA approval allows the product to be used in patients who have undergone at least six months of non-operative treatment, positioning it as a viable option for those seeking to overcome prolonged recovery periods.First U.S. Patient Treated with Cerapedics' PearlMatrix Cerapedics has also secured FDA approval for expanded indications and labeling for its i-FACTOR P-15 peptide enhanced bone graft, further solidifying their position in the market作者：JS Harrop·2025·被引用次数：1—P-15L, an FDA-designated Breakthrough Device, is a composite bone graft consisting of an anorganic bone mineral (ABM) and P-15, a 15-amino acid polypeptide, ....
The primary clinical application for PearlMatrix P-15 Peptide Enhanced Bone Graft is in lumbar interbody fusion procedures.Today we announced USFDA approvalofPearlMatrix™P-15 Peptide Enhanced Bone Graft, the first and only bone growth accelerator designed to ... It is intended for use in conjunction with approved spinal fixation systems, especially in cases where accelerating the fusion process is critical for patient recovery and long-term outcomes.2025年6月23日—Cerapedics received FDA premarket approvalof PearlMatrix P-15 Peptide Enhanced Bone Graft as a Class III drug/device combination product. The graft is designed for single-level TLIF (transforaminal lumbar interbody fusion) and has since gained approval for all major lumbar interbody fusion approaches.
Key advantages of PearlMatrix include:
* Accelerated Fusion: The P-15 peptide significantly speeds up the fusion process compared to traditional bone grafts, potentially reducing the time to fusion and improving patient mobilityAPPROVED FOR SINGLE-LEVEL TLIF · ACCELERATE IT. · It's A Race Against Time. ·PearlMatrixpowered byP-15 Peptideis the first and onlybonegrowth accelerator..
* Enhanced Osteogenic Potential: The peptide promotes cellular adhesion and proliferation, leading to more robust bone formation.
* Biocompatibility: As a synthetic peptide combined with anorganic bone mineral, it offers excellent biocompatibility.
* Breakthrough Device Status: Its designation as an FDA-designated breakthrough device highlights its innovative nature and therapeutic potential.
While the market offers various bone graft options, including autografts, allografts, and synthetic substitutes, PearlMatrix P-15 Peptide Enhanced Bone Graft stands out due to its unique peptide-enhanced mechanismBone and Tendon Graft Substitutes and Adjuncts. Unlike traditional grafts that rely on the inherent osteoconductive and osteoinductive properties of the material, PearlMatrix actively stimulates cellular activity through the P-15 peptide.
Cerapedics also offers the i-FACTOR Bone Graft, another product featuring the P-15 peptide, which has also received FDA approval and is backed by rigorous clinical data.Cerapedics received FDA premarket approvalfor PearlMatrix P-15 Peptide Enhanced Bone Graft, the first proven bone growth accelerator for lumbar fusion ... While both products leverage the P-15 peptide technology, PearlMatrix is specifically highlighted as a bone growth accelerator for lumbar fusion作者：JS Harrop·2025·被引用次数：1—P-15L, an FDA-designated breakthrough device, is a composite bone graft with P-15, a 15-amino acid polypeptide that promotes cellular adhesion, proliferation, .... The distinction lies in the precise formulation and intended application, with PearlMatrix positioned to offer a more potent acceleration of the fusion cascade.
The FDA approval of PearlMatrix P-15 Peptide Enhanced Bone Graft is a significant advancement for Cerapedics and for patients undergoing spinal fusion...FDAfor use in the lumbosacral spine. The system is to be used in patients who have had at least six months of non-operative treatment.PearlMatrix™Bone Graft.... It underscores the growing role of peptide-based biomaterials in regenerative medicine. Future research and clinical studies will likely continue to explore expanded indications and optimize its use across various spinal fusion techniques.
It is important to note that while the approval signifies a high level of safety and efficacy, any medical device carries potential risks. Patients and healthcare providers should engage in thorough discussions regarding the benefits, risks, and alternatives before proceeding with any surgical intervention involving PearlMatrix or any other bone graft substitute. Information regarding any Class 2 Device Recall should also be carefully considered, though these are typically related to labeling or minor quality control issues rather than fundamental product failure. The focus remains on the transformative potential of this peptide-enhanced bone graft in improving patient outcomes for complex spinal procedures.
Join the newsletter to receive news, updates, new products and freebies in your inbox.